{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T17:10:25Z","timestamp":1786209025823,"version":"build-2736575974"},"reference-count":109,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2022,3,4]]},"DOI":"10.1080\/13543776.2022.2026327","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T08:27:32Z","timestamp":1641457652000},"page":"299-315","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":49,"title":["Current trends of benzothiazoles in drug discovery: a patent review (2015\u20132020)"],"prefix":"10.1080","volume":"32","author":[{"given":"Christine Shing Wei","family":"Law","sequence":"first","affiliation":[{"name":"School of Science, Monash University Malaysia Campus, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0433-5070","authenticated-orcid":false,"given":"Keng Yoon","family":"Yeong","sequence":"additional","affiliation":[{"name":"School of Science, Monash University Malaysia Campus, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"issue":"1","key":"cit0001","first-page":"e1800170","volume":"352","author":"Tariq S","year":"2019","journal-title":"Arch Pharm"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2014.10.059"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25081909"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.03.023"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.2174\/1570178614666161205123900"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1111\/cbdd.13072"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1007\/s00044-017-1784-2"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.2174\/1567205018666210218151228"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1186\/s13065-018-0459-5"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202100004"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202100370"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2014.999764"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1021\/jm901241e"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1111\/cbdd.12260"},{"key":"cit0015","volume-title":"Heterocyclic chemistry in drug discovery","author":"Li JJ","year":"2013"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.05.011"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2016.02.001"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.4137\/PMC.S13384"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.3390\/ph13110394"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01286"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01732"},{"key":"cit0022","unstructured":"Novartis AG. Methods for using FXR agonists. 2017. (AU2017223154B2)."},{"key":"cit0023","unstructured":"Hepagene Therapeutics, Inc. Heterocyclic FXR modulators. 2019. (US2019\/0248752A1)."},{"key":"cit0024","unstructured":"Ardelyx, Inc. Hormone receptor modulators for treating metabolic conditions and disorders. 2020. (US10793568B2)."},{"key":"cit0025","unstructured":"Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators. 2018. (WO2018\/039384A1)."},{"issue":"1","key":"cit0026","first-page":"1","volume":"33","author":"Yu JE","year":"2018","journal-title":"Histol Histopathol"},{"key":"cit0027","unstructured":"Bristol-Myers Squibb Company. 2-(benzothiazol-2-yl)-2-cyano-acetamide derivatives and their use as endothelial lipase inhibitors. 2020. (US10597370B2)."},{"key":"cit0028","unstructured":"Columbia University of New York. Aldose reductase inhibitors and methods of use thereof. 2020. (US10647726B2)."},{"key":"cit0029","volume-title":"Pharmacokinetics and metabolism in drug design: methods and principles in medicinal chemistry. Germany","author":"Smith DA","year":"2003"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1080\/14756360701425014"},{"key":"cit0031","unstructured":"Korea Research Institute of Chemical Technology. 2-phenylimidazo[1,2-\u03b1]pyridine derivatives substituted with heteroaryl, preparation method thereof, and pharmaceutical composition for use in preventing or treating glucagon-like peptide 1 receptor activity related diseases containing the same as an active ingredient. 2018. (KR20180101671A)."},{"key":"cit0032","unstructured":"Sookmyung Women\u2019s University Industry Academic Cooperation Foundation. Novel benzoxazole or benzothiazole derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient. 2018. (KR101838615B1)."},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0954-x"},{"key":"cit0034","unstructured":"Institute of Pharmacology and Toxicology Academy of Military Medical Sciences. Novel thiazole derivates class compound, its preparation method, pharmaceutical composition and its pharmaceutical applications.2018. (CN107556267A)."},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01541"},{"issue":"1","key":"cit0036","first-page":"327","volume":"9","author":"Mendel DB","year":"2003","journal-title":"Clin Cancer Res"},{"key":"cit0037","unstructured":"Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor. 2016. (US2016\/0326162A1)."},{"key":"cit0038","unstructured":"Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof. 2020. (WO2020\/097398A1)."},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-019-02611-7"},{"key":"cit0040","unstructured":"Kancera AB. Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity. 2020. (US10654814B2)."},{"key":"cit0041","unstructured":"HB Therapeutics Inc. Compositions and methods for treating cancer. 2019. (WO2019\/217509A1)."},{"key":"cit0042","unstructured":"Araxes Pharma LLC. Benzothiophene and benzothiazole compounds and methods of use thereof. 2018. (WO2018\/140599A1)."},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100186"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061204"},{"issue":"3","key":"cit0045","first-page":"727","volume":"10","author":"Han Y","year":"2020","journal-title":"Am J Cancer Res"},{"key":"cit0046","unstructured":"Incyte Corporation. Heterocyclic compounds as immunomodulators. 2017 (CA3005727)."},{"key":"cit0047","unstructured":"Xiaohua W. Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof. 2019. (US10221168B1)."},{"issue":"5324","key":"cit0048","first-page":"1","volume":"10","author":"Schauer NJ","year":"2020","journal-title":"Sci Rep"},{"key":"cit0049","unstructured":"China Pharmaceutical University. Benzothiazole compound and medical application thereof. 2020. (CN111763201A)."},{"key":"cit0050","unstructured":"Northwestern Polytechnical University. 2-(N-ethyl)-6-trifluoromethoxy benzothiazoles as cancer therapy drug application. 2017. (CN107007598A)."},{"key":"cit0051","unstructured":"Henan University of Technology. The preparation method and applications of 4-heteroaryl qualone derivatives. 2018. (CN108003150A)."},{"key":"cit0052","unstructured":"Jinan University. A kind of 2-(3-aminophenyl)-benzothiazole derivant and its preparation method and application. 2018. (CN108727295A)."},{"key":"cit0053","unstructured":"Hunan Huateng Pharmaceutical Co. Ltd. Triazine compound and preparing method and antineoplastic application thereof.2015. (CN105175410A)."},{"key":"cit0054","unstructured":"University of Nottingham. Kunming University of Science and Technology, Jiangsu Atom Bioscience and Pharmaceutical Co. Ltd. Use of 4-(benzothiazol-2-yl)arylamine compound in treating stomach cancer. 2020. (WO2020098516A1)."},{"key":"cit0055","unstructured":"Bayer Pharma Aktiengesellschaft. Substituted 2-(1H-pyrazol-1-yl)-benzothiazole compounds. 2017. (WO2017\/063966A1)."},{"key":"cit0056","unstructured":"Bayer Pharma Aktiengesellschaft. Cytotoxic substituted 2-(1-pyrazol-1-yl)-1,3-benzothiazole compounds for the treatment of cancer. 2016. (WO2016\/202759A1)."},{"key":"cit0057","unstructured":"Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof. 2019. (US10246439B2."},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1735-6"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6106"},{"key":"cit0060","unstructured":"Second Military Medical University. A kind of benzothiazole analog derivative and application thereof. 2018. (CN109053630A)."},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00001"},{"key":"cit0062","unstructured":"Tesaro, Inc. Small molecule inhibitors of colony stimulating factor-1 receptor (CSF-1R) and uses thereof. 2018. (WO2018119387A1)."},{"key":"cit0063","unstructured":"Novartis AG. Methods for treating ocular disease using inhibitors of CSF-1R. 2020. (US10537563B2)."},{"key":"cit0064","unstructured":"The Regents of the University of California, Fondazione Istituto Italiano Di Tecnologia. Piperazinyl methanone NAAA inhibitors. 2020. (US10556892B2)."},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2017.12.009"},{"key":"cit0066","unstructured":"Bristol-Myers Squibb Company. Lactam, cyclic urea and carbamate, and triazolone derivatives as potent and selective ROCK inhibitors. 2020. (US10730858B2)."},{"key":"cit0067","unstructured":"Naegis Pharmaceuticals Inc. Leukotriene synthesis inhibitors. 2020. (WO2020146822A1)."},{"key":"cit0068","unstructured":"1ST Biotherapeutics, Inc. Benzothiazol compounds and methods using the same for treating neurodegenerative disorders. 2020. (US10669246B2)."},{"key":"cit0069","unstructured":"AC Immune SA. Novel compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates. 2019. (WO2019233745A1)."},{"key":"cit0070","unstructured":"Pharmasum Therapeutics AS. Benzothiazole derivatives as DYRK1 inhibitors. 2019. (US20190375742A1)."},{"key":"cit0071","unstructured":"Asceneuron SA. Sulfoximine glycosidase inhibitors.2018. (AU2017400271B2)."},{"key":"cit0072","unstructured":"Eli Lilly and Company. 6-fluoro 2-methylbenzo[d]thiazol-5-yl compounds.2020. (US10752632B2)."},{"key":"cit0073","unstructured":"Merck Sharp & Dohme Corp. Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors. 2018. (WO2018085171A1)."},{"key":"cit0074","unstructured":"PTC Therapeutics, Inc. Heteroaryl compounds for treating Huntington\u2019s disease. 2020. (WO2020005877A1)."},{"key":"cit0075","unstructured":"Viiv Healthcare UK (No.5). Limited. Inhibitors of human immunodeficiency virus replication. 2016. (AU2016250661B2)."},{"key":"cit0076","unstructured":"Viiv Healthcare (No.5). Limited. Inhibitors of human immunodeficiency virus replication. 2016. WO2016172425A1."},{"key":"cit0077","unstructured":"Viiv Healthcare (No.5). Limited. 5-(N-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication. 2019. (EP3334723B1)."},{"key":"cit0078","unstructured":"Gilead Sciences, Inc. Therapeutic compounds. 2020. (US10800772B2)."},{"key":"cit0079","unstructured":"Georgia State University Research Foundation, Inc., Aviragen Therapeutics, Inc. Bicyclic fused pyrazole derivatives for the treatment of RSV. 2017. (WO2017\/196982A1)."},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12503"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8010090"},{"key":"cit0082","unstructured":"Xixi Hospital of Hangzhou. One kind has the application of uracil-benzothiazole structure derivative, preparation method and anti-HCV medicament.2019. (CN110483496A)."},{"key":"cit0083","unstructured":"Antabio SAS. Chemical compounds as antibiotics.2020. (US20200155509A1)."},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2021.02.026"},{"key":"cit0085","unstructured":"Antabio SAS. Indane derivatives for use in the treatment of bacterial infection. 2020. (WO2020064174A1)."},{"key":"cit0086","unstructured":"The University of North Carolina, University of Washington. Compounds for treatment of trypanosomes and neurological pathogens and uses thereof. US10399966B2 (2019)"},{"key":"cit0087","unstructured":"Medisynergies LLC. Bicyclic antiparasitic compounds. 2019. (US10351552B2)."},{"key":"cit0088","unstructured":"PharmAkea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof. 2018. (WO2018048930A1)."},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201005673"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2018.11.005"},{"key":"cit0091","unstructured":"Hanmi Pharmaceutical Co. Ltd. Novel pyrazole derivatives as ALK5 inhibitor and uses thereof. 2018. (AU2017289021B2)."},{"key":"cit0092","unstructured":"Bristol-Myers Squibb Company. Benzothiazole and benzothiophene compounds. 2016. (WO2016138199A1)."},{"key":"cit0093","unstructured":"Bristol-Myers Squibb Company, Universit\u00e9 De Montr\u00e9al. Tricyclic heteroaryl-substituted quinolone and azaquinoline compounds as PAR4 inhibitors.2019. (US20190315774A1)."},{"key":"cit0094","unstructured":"Bristol-Myers Squibb Company. Bicyclic heteroaryl substituted compounds. 2020. (US10730868B2)."},{"key":"cit0095","unstructured":"Hoffmann-La F, Roche AG. Benzothiazole compounds for the treatment of autoimmune diseases. WO2020048583A1 (2020)"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91575-8"},{"key":"cit0097","unstructured":"Actelion Pharmaceuticals Ltd. 2,5-disubstituted benzoxazole and benzothiazole compounds as NADPH oxidase 4 inhibitors. EP3310767B1 (2016)"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22091397"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1517\/17460441.2012.678829"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.10.039"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2021.1916465"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2021.1884068"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25194394"},{"key":"cit0104","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-219006"},{"key":"cit0105","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004942"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12020142"},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.1007\/s12011-020-02394-3"},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111943"},{"issue":"2","key":"cit0109","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/2211068216677248","volume":"22","author":"Worzella T","year":"2017","journal-title":"SLAS Technol"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2022.2026327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,6]],"date-time":"2022-03-06T14:18:22Z","timestamp":1646576302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2022.2026327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,17]]},"references-count":109,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3,4]]}},"alternative-id":["10.1080\/13543776.2022.2026327"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2022.2026327","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}